Revolution Medicines, Inc. (RVMD)
| Market Cap | 39.21B +470.3% |
| Revenue (ttm) | n/a |
| Net Income | -1.37B |
| EPS | -7.12 |
| Shares Out | 212.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,536,596 |
| Open | 183.12 |
| Previous Close | 184.97 |
| Day's Range | 181.17 - 185.97 |
| 52-Week Range | 34.00 - 193.83 |
| Beta | 1.38 |
| Analysts | Strong Buy |
| Price Target | 200.27 (+8.58%) |
| Earnings Date | Aug 5, 2026 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $200.27, which is an increase of 8.58% from the latest price.
News
Revolution Medicines price target raised to $235 from $205 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $235 from $205 and keeps a Buy rating on the shares. The outlook for Revolution Medicines’…
EMA accelerates assessment of Revolution Medicines daraxonrasib
Revolution Medicines (RVMD) announced that European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has started a phased review of data on daraxonrasib, the company’s inves...
European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process
REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental treatment for patients with metastatic pancreatic cancer.
Revolution Medicines price target raised to $215 from $185 at Mizuho
Mizuho raised the firm’s price target on Revolution Medicines (RVMD) to $215 from $185 and keeps an Outperform rating on the shares after the company presented updated/initial Phase I/II data…
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines price target raised to $210 from $179 at Truist
Truist raised the firm’s price target on Revolution Medicines (RVMD) to $210 from $179 and keeps a Buy rating on the shares. The firm’s updated analysis of Revolution Medicines raises…
Revolution Medicines price target raised to $235 from $183 at Needham
Needham analyst Ami Fadia raised the firm’s price target on Revolution Medicines (RVMD) to $235 from $183 and keeps a Buy rating on the shares. The firm is incrementally more…
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announc...
Revolution Medicines begins treating patients in RASolute 305 trial
Revolution Medicines (RVMD) announced that it has begun treating patients in RASolute 305, a global, randomized Phase 3 clinical trial evaluating zoldonrasib in combination with standard of care chemo...
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strate...
RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position
RBC Capital notes that Tango Therapeutics (TNGX) announced data from the combo of their PRMT5 inhibitor vopimetostat and Revolution Medicines’ (RVMD) Marax or zoldon. The firm thinks the data supports...
Tango Therapeutics announces data from study of vopimetostat, daraxonrasib
Tango Therapeutics (TNGX) announced positive initial data from its ongoing Phase 1/2 study of vopimetostat, an investigational PRMT5 inhibitor with first- and best-in-class potential, in combination w...
Revolution Medicines price target raised to $182 from $165 at RBC Capital
RBC Capital raised the firm’s price target on Revolution Medicines (RVMD) to $182 from $165 and keeps an Outperform rating on the shares. The company’s daraxonrasib will be able to…
Wedbush reiterates Outperform on Revolution Medicines after ASCO data
Wedbush analyst Robert Driscoll notes that Revolution Medicines (RVMD) presented full RASolute-302 data at ASCO 2026 Plenary Session, with results published simultaneously in the NEJM, confirming the ...
Revolution Medicines price target raised to $195 from $169 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Revolution Medicines (RVMD) to $195 from $169 and keeps a Buy rating on the shares after the company presented the full results…
Revolution Medicines price target raised to $195 from $165 at Oppenheimer
Oppenheimer raised the firm’s price target on Revolution Medicines (RVMD) to $195 from $165 and keeps an Outperform rating on the shares. At ASCO 2026, additional RASolute-302 data strengthened daraxo...
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines' ...
Revolution Medicines Transcript: Study result
Daraxonrasib demonstrated a transformative survival benefit in metastatic pancreatic cancer, doubling median overall survival and progression-free survival versus chemotherapy, with a strong safety and tolerability profile. Regulatory submissions and global commercialization plans are advancing, while a broad pipeline and ongoing studies aim to expand impact across RAS-driven cancers.
Revolution Medicines Slides: Study result
Revolution Medicines has posted slides in relation to its latest quarterly earnings report, which was published on May 31, 2026.
Revolution Medicines Press release: Study result
Revolution Medicines issued a press release on May 31, 2026, disclosing material business information to investors.
Revolution Medicines announces results from Phase 3 RASolute 302 trial
Revolution Medicines (RVMD) announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients w...
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine
Revolution's pancreatic cancer drug doubles survival, boosts quality of life
Revolution Medicine's experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some patients could resume activities they had previously aband...
Bernstein starts Revolution Medicines at Market Perform, says upside baked in
Bernstein initiated coverage of Revolution Medicines (RVMD) with a Market Perform rating and $151 price target The firm believes investors should pass on RevMed at this time because the value…